Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 98%
filed 2026-06-03
Item 2.02
Macy's issued a press release on June 3, 2026 announcing financial results for the 13-week period ended May 2, 2026, including results of operations, financial condition, and cash flows. The disclosure explicitly references a press release attached as Exhibit 99.1 and includes both GAAP and non-GAAP financial measures (EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS), which is the standard format for quarterly earnings releases under Item 2.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-03
Item 5.02
The filing discloses the appointment of Dr. Anna Greka as a Class III director of Ovid Therapeutics, effective June 15, 2026, following Board approval on May 29, 2026. The principal disclosed action is a person taking a role (director and committee member), making this an executive appointment. Dr. Greka's appointment is material as it represents a change in board composition and governance structure, and her credentials as a Harvard Medical School professor with significant biotech experience would be relevant to investor assessment of the company's leadership.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 7.01
The disclosure confirms full-year 2026 guidance and provides a Q2 update showing low-single-digit comparable store sales growth tracking, along with a repurchase program status update ($20M of $50M authorized repurchased). While guidance confirmation and operational updates are material to investors assessing company performance, this does not fit neatly into the specific event categories (not an earnings release, not a restatement, not an M&A event, etc.). The Item 7.01 Regulation FD Disclosure format and forward-looking nature of the guidance, combined with the operational update on e-commerce migration and comparable sales trends, warrant classification as a material event that does not fit the more specific taxonomy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This is a clear disclosure of shareholder voting results from Crescent Biopharma's June 2, 2026 annual general meeting, filed under Item 5.07. The filing reports detailed vote tallies for four proposals: election of two Class II directors (Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. All proposals passed. This is material as director elections and auditor ratification directly affect corporate governance and investor confidence.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-03
Item 2.02
Virco Manufacturing Corporation disclosed its quarterly financial results for operations and financial condition as of the filing date of June 3, 2026, providing investors with essential performance metrics.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
Item 8.01
The filing discloses a dividend declaration of $9.96 per share, which is a material distribution to shareholders. While dividend declarations are routine for closed-end funds, this specific amount and the formal 8-K disclosure indicate materiality to investors. However, this does not fit cleanly into the standard taxonomy categories (it is not an earnings release, compensation arrangement, or other defined event type), warranting classification as "other_material."
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-03
Item 2.02
The filing explicitly discloses that Tilly's, Inc. issued an earnings press release for the first quarter ended May 2, 2026, furnished as Exhibit 99.1. This is a classic Item 2.02 earnings release disclosure, which is material to investors as it reports quarterly financial results.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-03
Item 8.01
Mineralys entered into an underwriting agreement on June 3, 2026 to issue 5,660,378 shares of common stock at $26.50 per share, with expected net proceeds of approximately $142.5 million. This is a registered public offering of equity securities that will dilute existing shareholders. The disclosure of the underwriting agreement, pricing, and expected closing date constitutes a material dilutive issuance event requiring 8-K disclosure under Item 3.02 (though filed under Item 8.01).
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 7.01
The disclosure announces receipt of a $25–$30 million order from an existing customer, which is material in scale and would affect a reasonable investor's assessment of near-term revenue and business momentum. However, the filing does not fit neatly into the standard taxonomy (not an earnings release, M&A activity, or other defined event type), and the cautionary language about future deployment timing and market conditions introduces uncertainty about execution. This is best classified as other_material.
View raw filing on EDGAR →
8-K
M&A activity
confidence 45%
filed 2026-06-03
Item 1.01
This Item 1.01 discloses entry into material definitive agreements—an amended bridge note increasing principal by $1M and a waiver of convertible note defaults with materially adverse terms (interest rate floor increased from 8% to 10%, default rate of 18%, automatic termination if Q1 10-Q not filed by October 1, 2026). While Item 1.01 typically covers M&A, the filing itself centers on debt restructuring and covenant waivers rather than acquisition or disposition activity. The most salient event is the material amendment to debt obligations and the waiver of defaults under convertible notes, which signals financial distress and increased creditor control.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 8.01
OPAL Fuels announced commencement of construction on two RNG facilities (50/50 joint venture with GFL Environmental) expected to produce 15 million gasoline gallon equivalents annually. This represents material capital deployment and expansion of the Company's RNG production and distribution infrastructure, which is central to its business strategy. While not a classic M&A transaction, the joint venture facility development and associated production capacity are material to investors assessing the Company's growth trajectory and operational scale.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from the Company's May 28, 2026 annual meeting. The filing reports final voting tallies for three proposals: election of two Class II directors (William A. Heyburn and Andrew Lauck), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. All three votes passed with substantial majorities, making this a routine but material governance disclosure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-03
Item 3.01
Cardlytics received formal notice from Nasdaq that its stock has closed below the $1.00 minimum bid price for 30 consecutive business days, triggering a delisting compliance notice under Nasdaq Listing Rule 5550(a)(2). The company has 180 days until November 30, 2026 to regain compliance or face delisting.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 3.03
Cardlytics effected a 1-for-10 reverse stock split and reduction in authorized shares, both approved by stockholders via Charter Amendment filed June 3, 2026. The reverse split is a material capital structure adjustment affecting share count and trading mechanics.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Agilon Health's annual meeting of stockholders held on June 2, 2026. The filing presents voting outcomes for three proposals: election of three Class II directors (Diana McKenzie, Karen McLoughlin, Ronald Williams), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This is a clear disclosure of shareholder vote results from Acumen Pharmaceuticals' June 3, 2026 annual meeting, covering three proposals: election of three Class II directors, ratification of Ernst & Young LLP as independent auditor, and approval of the Amended and Restated 2021 Equity Incentive Plan. The filing presents detailed voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This is a clear disclosure of shareholder voting results from FGI Industries' Annual General Meeting held on June 3, 2026. The filing presents tabulated vote counts for two matters: (1) election of five directors (David Bruce, John Chen, Todd Heysse, Kellie Zesch Weir, and Anagha Apte), and (2) ratification of Marcum Asia CPAs LLP as independent auditor. All five director nominees were elected with overwhelming support (1,387,347–1,387,581 votes for, zero against), and the auditor ratification passed with 1,606,497 votes for. This is a textbook Item 5.07 shareholder vote results disclosure, material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
KeyCorp is recasting segment financial information in its 2025 Form 10-K to reflect a change in segment reporting implemented in Q1 2026, specifically the reallocation of centrally managed interest rate risk from Consumer Bank and Commercial Bank segments to the Other segment. While the company explicitly states this is "not an amendment or restatement" and there is "no impact on the Company's consolidated financial statements," the recast affects how segment results are presented and disclosed, which is material to investors evaluating business unit performance. The filing is required under SEC rules when a registrant makes accounting changes and subsequently files new registration or proxy statements incorporating prior period financials.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This is a clear disclosure of shareholder voting results from Global Industrial Company's 2026 Annual Meeting of Stockholders held on June 1, 2026. Item 5.07 requires disclosure of the final voting results for all matters submitted to shareholders, including election of eight directors, ratification of Ernst & Young LLP as auditor, advisory vote on named executive officer compensation, and approval of the Amended and Restated 2018 Employee Stock Purchase Plan. The filing presents detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each matter, which is the standard format for shareholder vote result disclosures.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-06-03
Item 5.02
Raphael Thomas Wallander resigned as a Class III director and member of the Human Capital Management and Compensation Committee on May 28, 2026. The principal disclosed action is a director's departure from the board, which is material to investors as it affects board composition and governance. The context of his recent appointment in October 2025 in connection with a debt exchange transaction adds significance to the departure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This is a clear disclosure of shareholder vote results from Keros Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing reports final voting tallies for three proposals: election of two directors (Proposal 1), ratification of Deloitte & Touche LLP as auditor (Proposal 2), and advisory approval of executive compensation (Proposal 3), with specific vote counts for each. This is a quintessential Item 5.07 shareholder_vote_results disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 8.01
RadNet disclosed a proposed amendment to its First Lien Credit Agreement to add an incremental term loan of $200 million. While this represents a material financing event that would affect investor assessment of the company's capital structure and liquidity, it does not fit cleanly into the more specific categories (ma_activity applies to acquisitions/dispositions, dilutive_issuance to equity sales, covenant_breach to defaults). The amendment itself is a debt restructuring or refinancing activity that is material but lacks a dedicated taxonomy category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-03
Item 1.01
The filing discloses an amendment to an At-The-Market (ATM) Issuance Sales Agreement with Aegis Capital Corp., extending the term to allow continued issuance and sale of shares. ATM agreements are equity offerings that enable dilutive issuances of securities, and amendments extending such agreements signal the company's intent to raise capital through equity dilution. This is material to investors assessing capital structure and shareholder dilution risk.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
Valion Bio held its Annual Meeting of Stockholders on May 28, 2026, with shareholders voting on eight proposals including director elections, an amendment to the 2021 Equity Incentive Plan increasing authorized shares by 2,581,608, auditor ratification, and four Nasdaq Rule 5635(d) approvals for dilutive equity issuances to institutional investors and Tumim Stone Capital. All proposals passed.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-06-03
Item 1.01
High Wire Networks entered into a Securities Purchase Agreement on May 28, 2026, to sell 34 shares of Series G Preferred Stock at $1,000 per share plus 12 restricted shares as equity incentive, with initial closing on June 1, 2026. The unregistered private placement under Section 4(a)(2) and Regulation D Rule 506 involves convertible preferred equity carrying a 12% dividend rate, with additional tranches of up to 70 shares available, representing a significant dilutive capital raise.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This Item 5.07 disclosure reports the final voting results from Brighthouse Financial's June 2, 2026 Annual Meeting of Stockholders, covering three proposals: election of nine directors, ratification of Deloitte & Touche LLP as independent auditor, and an advisory say-on-pay vote. The detailed tabulation of votes for and against each director nominee and the three proposals is the core content of a shareholder vote results disclosure, which is material to investors assessing board composition and governance outcomes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-03
Item 3.02
This Item 3.02 disclosure describes an unregistered private placement of preferred stock under Regulation D Rule 506(b) to accredited investors. During the period May 18–June 2, 2026, the Company issued 366,016 shares of Series 2025 Preferred Stock for $3.6 million in aggregate proceeds, bringing total outstanding shares to 11.68 million. The ongoing best-efforts offering with a $150 million cap and the material cash proceeds make this a dilutive equity issuance material to investors assessing the Company's capital structure and financing activities.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-06-03
Item 7.01
Liberty Latin America disclosed the financial report of its wholly-owned subsidiary Liberty Communications PR Holding LP for the quarter ended March 31, 2026, made available on the company's investor relations website. This constitutes a quarterly earnings disclosure, which is material to investors assessing the registrant's financial performance and condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-03
Item 2.02
Broadcom disclosed unaudited financial results for Q2 2026 (ended May 3, 2026) via press release, providing quarterly financial performance data essential to assessing operating results and financial condition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-03
Item 2.01
Sadot Group completed the acquisition of 100% of Anira Consulting FZC for $12 million in aggregate consideration paid through stock and convertible debt. The acquisition includes the TradeOS CTRM platform and is material to the Company.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
Item 7.01
The filing discloses a corporate update on "NYSE compliance process and strategic transaction initiatives" via press release. While the Item 7.01 disclosure itself is vague, the reference to NYSE compliance suggests potential delisting risk or listing status concerns, and "strategic transaction initiatives" suggests possible M&A activity. Without access to the full press release (Exhibit 99.1), the most appropriate classification is other_material, as the disclosure touches on material matters (compliance and transactions) but the specific nature and materiality cannot be fully determined from the Item text alone.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-03
Item 1.01
British American Tobacco (BAT) acquired approximately 40.6% ownership of Charlotte's Web Holdings through a combination of: (1) purchase of 14,662,765 common shares for C$13.9 million under a Subscription Agreement dated March 30, 2026 (closed May 28, 2026); (2) conversion of a Convertible Debenture (originally issued November 14, 2022) into 95,281,277 common shares following amendment of conversion terms; and (3) amended investor rights including board nomination rights, registration rights, and standstill provisions. This represents a significant change of control event and material restructuring of the company's capital structure and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-03
Item 5.02
The disclosure centers on the appointment of Coree Thomas as Vice President and Chief Accounting Officer effective August 6, 2026, a principal accounting officer role. While the section also mentions Faez Kaabi's resignation, the substantive action disclosed is Thomas's appointment to a critical financial reporting position. The appointment of a principal accounting officer is material to investors assessing the company's financial reporting infrastructure and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
STEM held its 2026 Annual Meeting on June 3, 2026, with shareholders voting on four proposals: election of three Class II directors, approval of an amended equity incentive plan with 425,000 additional shares, advisory approval of named executive officer compensation, and ratification of RSM US LLP as independent auditor. Detailed voting results are disclosed for each proposal.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-03
Item 8.01
Cabaletta Bio disclosed clinical trial data and development updates for rese-cel across its autoimmune portfolio, including encouraging early preconditioning-free lupus findings and anticipated regulatory milestones (SSc registrational program initiation in 4Q26, DM/ASyS topline data in mid-2027, BLA submission in 2H27). For a clinical-stage biotech company, positive clinical trial results and development progress are material to investor assessment of pipeline value and regulatory prospects.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This is a textbook Item 5.07 disclosure of shareholder vote results from Grocery Outlet's June 1, 2026 annual meeting. The filing reports voting outcomes on four matters: (1) re-election of ten directors with detailed vote tallies, (2) ratification of Deloitte & Touche LLP as independent auditor, (3) advisory vote on named executive officer compensation, and (4) frequency of future advisory votes on executive compensation. All four proposals passed with substantial majorities. Shareholder vote results are material to investors as they reflect governance outcomes and stakeholder approval of key corporate matters.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-03
Item 2.02
The filing discloses ChargePoint's financial results for fiscal Q1 ended April 30, 2026, via a press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which would materially affect a reasonable investor's assessment of the company's operational and financial performance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This is a clear disclosure of shareholder vote results from UWM Holdings' Annual Meeting of Stockholders held on June 3, 2026. The filing reports voting outcomes for three proposals: election of four directors, ratification of Deloitte & Touche as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, and the detailed vote tallies are provided for each director nominee and proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Robinhood's 2026 Annual Meeting of Stockholders held on June 2, 2026. The filing presents voting results for three proposals: election of ten directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. All three proposals passed with substantial majorities, making this a material shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This is a clear disclosure of shareholder vote results from Torrid Holdings' June 2, 2026 annual meeting, including election of directors (Theophlius Killion and Michael A. Shaffer), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents detailed voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-03
Item 5.07
This Item 5.07 disclosure reports the final voting results from Rush Street Interactive's June 3, 2026 annual meeting of stockholders on three matters: election of four Class III directors, ratification of WithumSmith+Brown, PC as independent auditor, and approval of Charter Amendments. The detailed vote tallies for each proposal are the core content of the filing, which is the defining characteristic of a shareholder_vote_results event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 70%
filed 2026-06-03
Item 1.01
On June 2, 2026, Maravai LifeSciences entered into a new material definitive credit agreement providing $150 million in term loan and $30 million in revolving credit facilities, with proceeds used to refinance and terminate the prior October 2020 credit agreement. The refinancing materially affects the company's capital structure and financial obligations through 2032.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-06-03
Item 2.02
Petco disclosed quarterly financial results for the period ended May 2, 2026 via press release (Exhibit 99.1) and announced a scheduled webcast call with earnings presentation to discuss the quarter's financial performance.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
FortuneX Acquisition Corp consummated its IPO on May 26, 2026, raising $75 million in gross proceeds from 7.5 million units at $10.00 per unit, with simultaneous sponsor purchases of $2.975 million in private placement units. While this is a significant capital-raising event material to investors, it does not fit neatly into the standard taxonomy categories (earnings_release, ma_activity, dilutive_issuance). The disclosure is primarily informational about the IPO closing and trust account establishment rather than a forward-looking material event like a going concern or covenant breach. This is classified as other_material because it represents a transformational liquidity event for a SPAC that would affect investor assessment, but lacks a dedicated taxonomy category.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-03
Item 1.01
This Item 1.01 discloses entry into a Business Combination Agreement dated May 31, 2026, between Hall Chadwick Acquisition Corp (HCAC), its merger subsidiary, and REEcycle Holdings, Inc., a rare earth elements recycling company. The agreement contemplates a merger resulting in REEcycle as the surviving company, with HCAC domesticating from Cayman Islands to Delaware and merging with REEcycle. The transaction involves a $400 million purchase price with earnout provisions tied to production milestones, representing a material acquisition and change of control event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-03
Item 1.01
CXApp Inc.'s wholly owned subsidiary completed the acquisition of 100% of Virtus Digital Marketing Pty Ltd (EngineRoom) for approximately USD $4.6 million on June 3, 2026. The transaction materially expands the company's addressable market, increasing annualized revenue run-rate from ~$4 million to >$12 million and adding ~$1.6 million of adjusted EBITDA.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-03
Item 3.02
CXApp Inc. issued 12,267,843 shares of common stock to Avondale Capital, LLC under a Pre-Paid Purchase agreement dated October 17, 2025, at prices between $0.126216 and $0.126217 per share. The offering was made in reliance on Section 4(a)(2) of the Securities Act of 1933, indicating an unregistered private placement. This is a classic dilutive equity issuance that would materially affect shareholder ownership and is properly disclosed under Item 3.02.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 65%
filed 2026-06-03
Item 1.01
Nauticus Robotics entered into a Third Amendment to its convertible debt agreement, reducing the conversion price from $2.20 to $1.80 per share. This material modification to the Company's capital structure represents a dilutive adjustment that increases equity dilution risk to existing shareholders, consistent with a pattern of downward conversion price adjustments within nine months suggesting financial distress.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-03
Item 5.02
The disclosure centers on a special, one-time grant of 200,120 performance share units (PSUs) valued at $20 million to Jennifer F. Scanlon, the CEO, approved by the Board on June 1, 2026. This is a compensatory arrangement for a named executive officer involving equity grants with detailed vesting and performance conditions, which is the hallmark of exec_compensation under Item 5.02(e). The materiality is clear given the $20 million value and the five-year performance horizon tied to stock price and TSR metrics.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-03
Item 3.02
Blue Owl Real Estate Net Lease Trust sold 15.5 million common shares for approximately $164.6 million in gross proceeds on June 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from registration.
View raw filing on EDGAR →